RECOMMENDATION

Her Excellency the Governor General recommends to the House of Commons the appropriation of public revenue under the circumstances, in the manner and for the purposes set out in a measure entitled “An Act respecting pharmacare”.

Short Title

Marginal note:Short title

1 This Act may be cited as the Pharmacare Act.

Definitions

Marginal note:Definitions

2 The following definitions apply in this Act.

Indigenous peoples

Indigenous peoples has the meaning assigned by the definition aboriginal peoples of Canada in subsection 35(2) of the Constitution Act, 1982. (peuples autochtones)

Minister

Minister means the Minister of Health. (ministre)

pharmacare

pharmacare means a program that provides coverage of prescription drugs and related products. (régime d’assurance médicaments)

pharmaceutical product

pharmaceutical product means a prescription drug or related product that is funded, in whole or in part, through a pharmacare agreement to which the Government of Canada is a party. (produit pharmaceutique)

Purpose and Principles

Marginal note:Purpose

3 The purpose of this Act is to guide efforts to improve, for all Canadians, the accessibility and affordability of prescription drugs and related products, and to support their appropriate use, in collaboration with the provinces, territories, Indigenous peoples and other partners and stakeholders, with the aim of continuing to work toward the implementation of national universal pharmacare. Its purpose is also to support the development of a national formulary of essential prescription drugs and related products and to provide for the development a national bulk purchasing strategy.

Marginal note:Principles

4 The Minister is to consider the following principles and the Canada Health Act when collaborating with provinces, territories, Indigenous peoples and other partners and stakeholders with the aim of continuing to work toward the implementation of national universal pharmacare:

• (a) improve the accessibility of pharmaceutical products, including through their coverage, in a manner that is more consistent across Canada;

• (b) improve the affordability of pharmaceutical products, including by reducing financial barriers for Canadians;

• (c) support the appropriate use of pharmaceutical products — namely, in a manner that prioritizes patient safety, optimizes health outcomes and reinforces health system sustainability — in order to improve the physical and mental health and well-being of Canadians; and

• (d) provide universal coverage of pharmaceutical products across Canada.

Funding

Marginal note:Funding commitment

5 The Government of Canada commits to maintaining long-term funding for the provinces, territories and Indigenous peoples to improve the accessibility and affordability of pharmaceutical products, beginning with those for rare diseases. The funding for provinces and territories must be provided primarily through agreements with their respective governments.

Marginal note:Payments

• 6 (1) The Minister must, if the Minister has entered into an agreement with a province or territory to do so, make payments to the province or territory in order to increase any existing public pharmacare coverage — and to provide universal, single-payer, first-dollar coverage — for specific prescription drugs and related products intended for contraception or the treatment of diabetes.

• Marginal note:For greater certainty

  (2) For greater certainty, any agreement referred to in subsection (1) with a province or territory is to provide for first-dollar coverage to patients.

• Marginal note:Payment out of C.R.F.

  (3) Any amount payable under subsection (1) may be paid by the Minister out of the Consolidated Revenue Fund at the times and in the manner, and on any terms, that the Minister considers appropriate.

Minister’s Powers and Obligations

Marginal note:Request for advice

7 The Minister must seek advice from the Canadian Drug Agency on

• (a) the clinical effectiveness and cost-effectiveness of prescription drugs and related products compared to other treatment options;

• (b) the prescription drugs and related products that should be included in prescription drug coverage plans in Canada and the conditions of that coverage;

• (c) the collection and analysis of data on prescription drugs and related products;

• (d) information and recommendations to be provided to health care practitioners and patients on the appropriate use of prescription drugs and related products; and

• (e) improvements to be made to the pharmaceutical system, including through greater coordination between health system partners, patients and other stakeholders.

Marginal note:National formulary

• 8 (1) The Minister must, after discussions with the provinces and territories, request that the Canadian Drug Agency prepare, no later than the first anniversary of the day on which this Act receives royal assent, a list of essential prescription drugs and related products to inform the development of a national formulary that will establish the scope of prescription drugs and related products to which Canadians should have access under national universal pharmacare.

• Marginal note:Discussions

  (2) The Minister must, after the list referred to in subsection (1) has been prepared, initiate discussions based on the list with provinces, territories, Indigenous peoples and other partners and stakeholders with the aim of continuing to work toward the implementation of national universal pharmacare.

Marginal note:National bulk purchasing strategy

9 The Minister must, after discussions with the provinces and territories, request that the Canadian Drug Agency develop, in collaboration with partners and stakeholders and no later than the first anniversary of the day on which this Act receives royal assent, a national bulk purchasing strategy for prescription drugs and related products to support the principles set out in paragraphs 4(a) to (d).

Appropriate Use Strategy

Marginal note:Publication

• 10 (1) The Minister must, no later than the first anniversary of the day on which this Act receives royal assent, publish on the website of the Department of Health a pan-Canadian strategy regarding the appropriate use of prescription drugs and related products.

• Marginal note:Progress reports

  (2) The Minister may, after discussions with the provinces and territories, request that the Canadian Drug Agency prepare, no later than the third anniversary of the day on which the strategy is published and no later than every three years following that anniversary, a report on the progress made in advancing that strategy.

Committee of Experts

Marginal note:Committee of experts

• 11 (1) The Minister must, no later than 30 days after the day on which this Act receives royal assent, establish a committee of experts, and provide for its membership, to make recommendations respecting options for the operation and financing of national, universal, single-payer pharmacare.

• Marginal note:Report

  (2) The committee must, no later than the first anniversary of the day on which this Act receives royal assent, provide a written report to the Minister setting out its recommendations.

• Marginal note:Tabling of report

  (3) The Minister must cause a copy of the report to be tabled in each House of Parliament on any of the first 20 days on which that House is sitting after the day on which the Minister receives the report.